• Immunocore Holdings PLC IMCR.OQ reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -93 cents to 7 cents per share.

• Revenue rose 19.8% to $84.05 million from a year ago; analysts expected $85.91 million.

• Immunocore Holdings PLC's reported EPS for the quarter was a loss of 47 cents​.

• The company reported a quarterly loss of $23.77 million.

• Immunocore Holdings PLC shares had fallen by 1.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.2% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Immunocore Holdings PLC is $67.00

This summary was machine generated from LSEG data February 26 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)